


## THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

	Eligibility Criteria (see Section 3.2)	<b>Required Initial Laboratory Values</b>	
٠	Clinical stage II or III rectal adenocarcinoma defined as T4N0,	ANC	$\geq 1500/\text{mm}^3$
	or any T with node positive disease (any T, N+); also T3N0	Platelet count:	$\geq 100,000/\text{mm}^3$
	requiring APR or coloanal anastomosis	Creatinine:	$\leq$ 1.5 x upper limit of
٠	No prior systemic chemotherapy, targeted therapy, or		normal (ULN) OR
	immunotherapy; or radiation therapy administered as treatment	Calc. creatinine	$\geq$ 50 mL/min
	for colorectal cancer within the past 5 years	clearance:	
٠	Not pregnant and not nursing	Total bilirubin:	$\leq$ 1.5 x ULN
٠	Age $\geq 18$ years	AST/ALT:	$\leq$ 3 x ULN
٠	ECOG Performance Status 0-1		
٠	No upper rectal tumors (distal margin of tumor > 12 cm from		
	the anal verge)		
٠	No recurrent rectal cancer; prior transanal excision, prior distal		
	sigmoid cancer with a low anastomosis		
٠	No known mismatch repair deficient rectal adenocarcinoma		
	*		

Schema



 Patients with locally advanced rectal cancer: <=12cm, T4N0 OR anyT, N1 OR T3N0 that would require APR or coloanal anastomosis

- \*\* LCRT = long-course chemoradiation (5 weeks)
- \*\*\*mFOLFOX6 = 8 cycles (1 cycle = 2 weeks)
- \*\*\*\*mFOLFIRINOX = 8 cycles (1 cycle = 2 weeks)
- # CAPOX = 5 cycles (1 cycle = 3 weeks)

Treatment is to continue for the full course of LCRT and Arm 1 or Arm 2 chemotherapy unless there is a clinical reason to stop. Following neoadjuvant chemotherapy, patients will either proceed to surgery (TME) or watch & wait (WW). Patients will be followed for 8 years or until death, whichever comes first.

## Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

LCRT, chemotherapy (as noted in Arm 1 or Arm 2) and surgery will be conducted at the registering institution.

If the Group credited for enrollment is a non-Alliance Group, then other requirements from the credited Group may apply.

Version Date: 10/21/2022